Lauren Harshman
![Lauren Harshman](https://res.cloudinary.com/pcf/images/w_300,h_300,c_scale/fl_lossy/f_auto,q_auto/v1674665432/Harshman_DFCI-Headshot1-Oct2012_512x512_nrum1o_1874314268/Harshman_DFCI-Headshot1-Oct2012_512x512_nrum1o_1874314268.jpg?_i=AA)
About Lauren Harshman
- Immunotherapy has come of age with the approval of Sipuleucel-T (Provenge) and the introduction of ipilimumab (Yervoy) and other similar immune modulators into clinical trials for advanced metastatic prostate cancer.
- Dr. Harshman will study the biologic activities of a genetically-modified prostate tumor cell vaccine in the setting of Xtandi (enzalutamide) therapy for advanced, metastatic prostate cancer.
- These translational investigations, while developing a new therapy for patients, will also result in a biological understanding of the mechanisms of sensitivity and resistance to immunotherapy for prostate cancer. What this means for patients: A new immunotherapy will be developed for advanced, metastatic prostate cancer.
What this means for patients: A new immunotherapy will be developed for advanced, metastatic prostate cancer.
Award
2013 PCF Young Investigator
Lauren Harshman, MD
Dana-Farber Cancer Institute
Mentors
Philip Kantoff, MD and Christopher Sweeney, MBBS
Project Title
Clinical exploration of innovative targeted and immune modulating therapies in prostate cancer